A 44-week Monocentric Open Study Assessing the Efficacy and Safety of Deucravacitinib in Adults With Inflammatory Genodermatoses

NCT06136403 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Epidermolysis Bullosa Simplex
Ichthyosis
Genodermatosis
Inflammatory Congenital Ichthyoses

Interventions

DRUG: deucravacitinib

Sponsor

Centre Hospitalier Universitaire de Nice